GLP-1 e Glucagon: A Technical Pros and Cons Analysis
Published: 15 7 月, 2026 17:19
Author: Deepa Wagner
Abstract: This technical analysis evaluates GLP-1 and glucagon dual-agonists, focusing on peptide composition, market trends, and brand comparisons (e.g., Novo Nordisk vs. Eli Lilly). Pros include enhanced glycemic control and weight loss; cons involve gastrointestinal side effects and manufacturing complexity. Parameter comparisons highlight receptor selectivity and half-life. Regulatory certifications (FDA/EMA) and factory GMP compliance are critical for quality. Logistics require cold-chain integrity. Market data projects 15% CAGR (2024–2030), driven by obesity and diabetes applications. Selection criteria prioritize purity (>98%), stability, and clinical trial validation.